Abbott India, Sun Pharma, Lupin, GlaxoSmithKline & Cipla in tight contest at Pharmaleaders Awards

MUMBAI, India - Dec. 1, 2014 - PRLog -- Abbott India, Sun Pharma, Lupin, GlaxoSmithKline & Cipla in tight contest at Pharmaleaders 2014 Awards in top categories

The race to the coveted & credible award for India’s Most Admired & Powerful Brand, Corporate Practice, Investor Relations intensifies at 7^th Annual Pharmaceutical Leadership Summit & Awards
Tuesday,2^nd November 2014, Mumbai, Maharashtra : Pharmaleaders is back again like every year with a bang & this time with a yet another message. The Message is very loud & clear. Healthcare has no substitutes & Pharmaleaders means business. With the new Modi Government at the Centre, Pharmaleaders is hopeful of a plethora of reforms to see india smiling both by companies & patients. Pharmaleaders voce the opinion of Less Regulation, Less Bureaucracy & more & more easing of business transactions. Unlike last year, this Summit is debating on two important Sessions. in a uniquely positioned full day program encompassing two themes “Make In India – Healthcare Reforms , Insurance,Innovations,Investments & Infrastructure” & Empowering India’s Developing Healthcare System - Investing the Healthcare Solutions of Tomorrow in difficult Times at the Sahara Star, Mumbai International Airport in Mumbai, India, on December,26th , 2014. This historic Summit is supported by the Government of India at the Centre & is actively supported  by the Ministry of Health &  Family Affairs, Govt of India, Ministry of Commerce Pharmaceuticals , Government of india & host of other trade bodies. With more than 20 categories in voting by the stakeholders which includes the professionals of the pharmaceutical industry, healthcare analysts, consumers, stock analysts, medical Practitioners, Consultants, Hospital & Nursing Homes, india’s top Pharma majors with a significant command in the market share such as Abbott India Limited, Sun Pharmaceutical Industries, Glaxo Smithkline, Cipla are running neck to neck to chose the selection.

Speaking on the awards & process mechanism that follows the voting trends, Satya Brahma, Chairman & Editor-In-Chief Pharmaleaders said,” Pharma Leaders Awards has an established record of leadership in research, innovation and in ongoing improvements to health services through strong healthcare leadership. These Awards seek to recognise outstanding health leadership by an individual or team resulting in positive change across the global health system. Pharma Leaders Awards attempt to  recognize outstanding individual and team contributions across priority areas selected by the Pharmaleaders Jury. The Pharma leaders  Award recognises outstanding leadership, by an individual or Companies for a distinctive recognition in a clear exhibition of top performances in various verticals.Now in its 7th year, Pharma Leaders Awards received entries from healthcare corporations, hospitals, Medical Professionals, Research Scientist, and other allied disciplines listed in the award categories.”

“Pharma Leaders Awards Grand Jury is comprised of a panel of international industry experts,  representing the top creative minds in the field of healthcare, pharma academia, policy formation & the representatives from the  government. Each year, in addition to online judging sessions, the Pharma Leaders Awards organizes live judging  sessions around the globe to review digital based works as well as collateral materials that support a campaign and which cannot be judged online.

Indian Pharma industry is very competitive & the Road ahead For the Indian Pharma Sector is very tough given the regulatiory & pricing issue  Remaining  the Biggest challenges.Althe five players are strong in their respective therapeutic segments mainly consolidated after the biggest takeovers by Abbott India, Sun Pharma, Lupin, GlaxoSmithKline barring Cipla which continue to focus on internal branding of home grown products. Abbott India Limited is engaged in the discovery, development, manufacture and marketing of pharmaceutical, nutritional, hospital, and diagnostic products. It has six divisions. The Company’s products and therapeutics include Thyroid, Diabetes and Urology products includes Hytrin, Obimet, Thyrocab, Thyrocal D3 and Thyronorm; Pain Management products includes Brufen, Brugel and Bruspaz; Vitamins, include Multi- Vitamins combinations for diverse patient population; Anti-infectives products include portfolio comprises of various Antibiotics; Anaesthesia products includes Sevorane for induction and maintenance of general anaesthesia in adult and paediatric patients, for in-patient an outpatient surgery; Neonatology products includes Survanta and Others, include Allergy, Anti Coagulant, Cardiology, Immunology and Virology.

GlaxoSmithKline Pharmaceuticals product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas, such as anti-infectives, dermatology, gynaecology, diabetes, cardiovascular disease and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus and others. Revolade is for the treatment of thrombocytopenia in adults with the blood disorder chronic immune thrombocytopenic purpura. The Company has two research and development (R&D) units, which include Chemistry Research & Development and Pharmaceutical Research & Development.

Cipla Limited introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin acetate injection) for new antifungal for life-threatening fungal infections; Endobloc (ambrisentan tablets); Esomac (esomeprazole tablets); Evocort (formoterol and mometasone rotacaps)-new once-daily asthma controller therapy; Isablac (lactulose and isphaghula husk granules), and Ivabeat (ivabradine tablets) drug for coronary artery disease and chronic heart failure.

Sun Pharmaceutical Industries manufactures and markets pharmaceutical formulations as branded generics, as well as generics in India, the United states and several other markets across the world. The Company’s business is divided into four segments: US Generics,

Lupin produces a range of generic and branded formulations and bulk drugs. The Company along with its subsidiaries has manufacturing locations spread across India and Japan with trading and other incidental and related activities extending to world markets.

The Award ceremony is scheduled at 07.00 PM on 26th December 2014 onwards at the Grand Jade Room of Hotel sahara Star, Mumbai, India. Like every year, this will be attended by more than 300 power packed Healthcare Leaders in all disciple in the glittering award night followed by cocktail & Dinner.